key: cord-0918403-p7amf2h8 authors: Müller, Christin; Obermann, Wiebke; Karl, Nadja; Wendel, Hans-Guido; Taroncher-Oldenburg, Gaspar; Pleschka, Stephan; Hartmann, Roland K.; Grünweller, Arnold; Ziebuhr, John title: The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo date: 2021-01-08 journal: Antiviral Res DOI: 10.1016/j.antiviral.2021.105012 sha: 2165074e877e172a90ed408f54859d95ca6b65d6 doc_id: 918403 cord_uid: p7amf2h8 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of COVID-19, a severe respiratory disease with varying clinical presentations and outcomes, and responsible for a major pandemic that started in early 2020. With no vaccines or effective antiviral treatments available, the quest for novel therapeutic solutions remains an urgent priority. Rocaglates, a class of plant-derived cyclopenta[b]benzofurans, exhibit broad-spectrum antiviral activity against multiple RNA viruses including coronaviruses. Specifically, rocaglates inhibit eukaryotic initiation factor 4A (eIF4A)-dependent mRNA translation initiation, resulting in strongly reduced viral RNA translation. Here, we assessed the antiviral activity of the synthetic rocaglate CR-31-B (-) against SARS-CoV-2 using both in vitro and ex vivo cell culture models. In Vero E6 cells, CR-31-B (-) inhibited SARS-CoV-2 replication with an EC(50) of ∼1.8 nM. In primary human airway epithelial cells, CR-31-B (-) reduced viral titers to undetectable levels at a concentration of 100 nM. Reduced virus reproduction was accompanied by substantially reduced viral protein accumulation and replication/transcription complex formation. The data reveal a potent anti-SARS-CoV-2 activity by CR-31-B (-), corroborating previous results obtained for other coronaviruses and supporting the idea that rocaglates may be used in first-line antiviral intervention strategies against novel and emerging RNA virus outbreaks. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the genus Betacoronavirus (Gorbalenya et al., 2020) , causes a potentially severe respiratory illness, coronavirus disease 2019 , with case fatality rates ranging from 0.5% to 1% according to recent estimates (Rajgor et al., 2020 , Meyerowitz-Katz et al., 2020 . Following its rapid global spread, the World Health Organization declared COVID-19 a pandemic in March 2020 (WHO, 2020) . To date, no approved therapeutic is available against any human coronavirus but a number of investigational antiviral compounds that target viral functions have entered clinical trials (Brown et al., 2019 , de Wit et al., 2020 , Sheahan et al., 2017 , de Wilde et al., 2014 , Choy et al., 2020 , Sanders et al., 2020 . Moreover, compounds that modulate the human immune system and/or have an anti-inflammatory effect are also being tested for their potential to reduce the severity of COVID-19 progression (Oldenburg and Dohan, 2020 , Guaraldi et al., 2020 , Jalkanen et al., 2020 , Lam et al., 2020 . Finally, antivirals that target host mechanisms critical to viral replication are being developed, including inhibitors targeting host proteases required to activate the fusogenic activity of the SARS-CoV-2 spike protein (Bestle et al., 2020 , Hoffmann et al., 2020 . We and others have focused on approaches that inhibit viral protein synthesis, another host function critical to viral proliferation. Incidentally, a recently published SARS-CoV-2 protein interaction map identified the host translational machinery as a top target for repurposing drugs to block SARS- CoV-2 (Gordon et al., 2020) . In particular, two eukaryotic factors involved in the initiation phase of translation, eukaryotic initiation factor-1A (eIF1A) and eukaryotic initiation factor-4A (eIF4A), have been singled out for further development. eIF1A is a small protein that binds to the 40S ribosome subunit-mRNA complex (Gordon et al., 2020) , and eIF4A is a DEAD-box RNA helicase central to the activity of the eukaryotic translation initiation complex eIF4F (Chu and Pelletier, 2015) . As of this writing, the eIF1A inhibitor aplidin (PharmaMar) has entered a Phase 2 clinical trial for the treatment of COVID-19, and the eIF4A inhibitor zotatifin (eFFECTOR Therapeutics) is undergoing evaluation for potential COVID-19 clinical development (Harrison, 2020, Bronstrup and Sasse, 2020) . We recently demonstrated the antiviral potency of rocaglates, a class of natural and synthetic compounds, against MERS-CoV and the common cold human coronavirus HCoV-229E in vitro and ex vivo (Müller et al., 2018a , Müller et al., 2020 . Natural (e.g. rocaglamide A, silvestrol) and synthetic rocaglates (CR-31-B (-), zotatifin) are highly specific nanomolar eIF4A inhibitors. Rocaglates form stacking interactions with polypurine sequences in the 5′untranslated regions (UTRs) of capped mRNAs, clamping the mRNAs onto eIF4A and stalling mRNA unwinding, which results in a dissociation of the mRNA-eIF4A complex from eIF4E and eIF4G. Because eIF4A-mediated translation is key to the activation of a majority of oncogenes, several of these selective rocaglates are in preclinical cancer studies and at least one compound, zotatifin, has been advanced into early stage clinical studies J o u r n a l P r e -p r o o f (Bordeleau et al., 2008 , Lucas et al., 2009 , Kogure et al., 2013 , Patton et al., 2015 , Ernst et al., 2020 . Many viral RNAs contain 5'-UTRs with stable RNA structures (Madhugiri et al., 2016 , Schlereth et al., 2016 and are thus dependent on eIF4A for translation. Silvestrol exhibits broad-spectrum antiviral activity against a range of RNA viruses such as Ebola virus, Zika virus, Chikungunya virus, Crimean Congo hemorrhagic fever virus, Lassa virus, hepatitis E and several coronaviruses (Biedenkopf et al., 2017 , Elgner et al., 2018 , Henss et al., 2018 , Müller et al., 2020 , Glitscher et al., 2018 , Todt et al., 2018 , Müller et al., 2018a . While silvestrol and other natural rocaglates represent promising therapeutic leads due to their activities in the low nanomolar range and high selectivity indices (≥ 100) in primary cells, their natural availability is limited (Pannell, 1998) and their chemical synthesis is challenging due to their complex structures (Adams et al.,2009 , Pan et al., 2014 . As an alternative, a variety of synthetic rocaglate analogs have been generated that exhibit similar or enhanced eIF4A-targeting characteristics and can be produced to high purity and in large quantities. Recently, we compared the antiviral activity of silvestrol with that of CR-31-B (-), which lacks the dioxane moiety of silvestrol and makes it structurally less complex and more straightforward to synthesize (Wolfe et al., 2014) . We were able to show that, similar to silvestrol, CR-31-B (-) inhibits the replication of a range of RNA viruses both in vitro and ex vivo (Müller et al., 2020) . Here, we evaluated the potential activity of the synthetic rocaglate CR-31-B (-) against SARS-CoV-2 using both in vitro and human ex vivo cell culture systems. In a first set of experiments, we analyzed potential inhibitory effects of CR-31-B (-) which is under control of an eIF4A-independent IRES element from HCV. The short and unstructured 5´-UTR of the beta-globin gene and an unstructured (AC) 15 sequence served as negative controls, since these 5'-UTR sequences were shown to be not repressible upon inhibition of eIF4A (Müller et al., 2018a (Müller et al., , 2020 . The polypurine sequence (AG) 15 was used as a positive control since this sequence can be efficiently clamped onto the surface of eIF4A by different rocaglates due to π-π stacking interactions (Iwasaki et al., 2019 , Müller et al., 2020 . Using this experimental setup, eIF4A-dependency can be inferred from sensitivity of firefly luciferase mRNA translation to the presence of a specific eIF4A inhibitor. The data revealed that the 5'-UTRs of SARS-CoV-2, HCoV-229E and MERS-CoV were similarly sensitive to eIF4A-dependent translation inhibition by CR-31-B (-) in the dual luciferase reporter assay, when 10 nM CR-31-B (-) was used (Fig. 1C) , indicating that CR-31-B (-) may have also antiviral activity against SARS-CoV-2. To analyze possible antiviral effects of CR-31-B (-) in cell culture, African green monkey Vero E6 cells were used (Ogando et al., 2020) . No major cytotoxicity was detected for concentrations of up to 100 nM, with cell viability being reduced by about 10 -25 % at this highest concentration tested ( Fig. 2A) . Moreover, the production of infectious SARS-CoV-2 progeny was found to be reduced in a dose-dependent manner with an EC 50 of ~1.8 nM (Fig. 2B ), which is in a similar range as the CR-31-B (-) EC 50 values reported previously for other coronaviruses (~2.9 nM for HCoV-229E; ~1.9 nM for MERS-CoV) (Müller et al., 2020) . The selectivity index (CC 50 / EC 50 ) for SARS-CoV-2-infected Vero E6 cells was determined to be The discovery and development of antivirals that target host mechanisms critical to viral proliferation is of growing importance. The rationale behind this approach is twofold: first, host mechanisms are not virus-specific, but are used by a broad range of viruses, and second, targeting a host mechanism preempts the risk for developing resistance typically associated with targeting viral structures or mechanisms. Several host-targeting approaches against SARS-CoV-2 are currently under investigation. Most of these represent efforts to repurpose approved drugs with known safety profiles. Here, we added to the antiviral toolbox against SARS-CoV-2 the synthetic rocaglate CR-31-B (-), a specific inhibitor of eIF4A-dependent mRNA translation. We identified CR-31-B (-) as a potent and non-cytotoxic inhibitor of SARS-CoV-2 replication in vitro and ex vivo. The observed antiviral activities are directly comparable to those that we reported previously for other coronaviruses, namely HCoV-229E and MERS-CoV, and a range of highly pathogenic positive-and negative-sense RNA viruses. To our knowledge, this is the first report of a rocaglate inhibiting SARS-CoV-2 proliferation in a relevant ex vivo human bronchial cell system. Against the backdrop of a number of reports we and others have published over the past three years documenting the broad-spectrum antiviral activity of CR-31-B (-) and related rocaglates, the data we report here strengthen the case for the potential use of rocaglates as first-line, broad-spectrum 'pan-antivirals'. The necessary next step is the in vivo evaluation of CR-31-B (-) and other rocaglates to confirm safety and determine appropriate dosing regimens. Extensive preclinical work with CR-31-B (-), zotatifin, and other rocaglates as cancer therapeutics is a priori highly encouraging for the potential antiviral application of rocaglates in humans. Minimal or no toxicities were reported for long-term dosing regimens in animal models, along with favorable safety, ADME-and bioavailability profiles (Wolfe et al., 2014 , Chan et al., 2019 , Rodrigo et al., 2012 . In addition, the advancement of zotatifin into the clinic supports the potential of this class of molecules to be used as antivirals in humans. In summary, the path to clinical implementation is still long and will most likely require further optimization of CR-31-B (-) or other lead rocaglates currently under investigation. Nevertheless, the antiviral efficacy against viruses from diverse families, the low toxicity of this class of compounds both in vitro and ex vivo, and the ongoing advanced efforts to harness their activity as cancer therapeutics lead us to suggest that rocaglates represent a potentially powerful addition to the toolbox of therapeutic options for mitigating the consequences of global outbreaks by newly emerging RNA viruses. The authors declare no conflict of interest. The work was supported by the LOEWE Center DRUID (projects A2 and B2 to A.G. and as a positive control. Experiments were performed using previously described protocols (Müller et al., 2018a , Müller et al., 2020 with at least three independent biological replicates. Total synthesis of the potent anticancer Aglaia metabolites (-)-silvestrol and (-)-episilvestrol and the actice analogue (-)-4´-desmethoxyepisilvestrol TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells The natural compound silvestrol is a potent inhibitor of Ebola virus replication Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model Natural products targeting the elongation phase of eukaryotic protein biosynthesis Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma Remdesivir, Iopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection Inhibition of Zika Virus Replication by Silvestrol Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase Inhibition of Hepatitis E Virus Spread by the Natural Compound Silvestrol The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV Tocilizumab in patients with severe COVID-19: a retrospective cohort study Drug researchers pursue new lines of attack against COVID-19 Silvestrol Inhibits Chikungunya Virus Replication SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor The Translation Inhibitor Rocaglamide Targets a Bimolecular Cavity between eIF4A and Polypurine RNA Interferon beta-1a for COVID-19: critical importance of the administration route Coronaviruses and the human airway: a universal system for virus-host interaction studies Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo Coronavirus cis-acting RNA elements A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates Inhibition of cytosolic phospholipase A2alpha impairs an early step of coronavirus replication in cell culture Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (-) and the eIF4A-inhibitor Silvestrol Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona-and picornaviruses replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species Aglaia foveolate. The IUCN Red List of Threatened Species The eukaryotic translation initiation factors eIF1 and eIF1A induce an open conformation of the 40S ribosome The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBVdriven lymphoproliferative disease The many estimates of the COVID-19 case fatality rate Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review Azithromycin for severe COVID-19 RNA binding specificity of Ebola virus transcription factor VP30 Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer World Health Organization. Coronavirus sease 2019 (COVID-19) situation report-51 We thank Ulrike Wend for her excellent technical assistance.